Table 1.

Plant natural products and derivatives approved by the U.S. FDA from 2011 to mid-2013^a

Year Approved	Generic Name	Natural or Lead Compound	Trade Name	Indication
2011	ioflupane I-123b	cocaine	Datscan®	brain imaging in suspected Parkinsonian syndromes
2011	gabapentin enacarbilb	gamma-aminobutyric acid (GABA)	Horizant®	restless leg syndrome
2012	ingenol mebutateb	ingenol-3-angelate	Picato®	actinic keratosis
2012	lorcaserin hydrochlorideb	ephedrine	Belviq®	obesity
2012	omacetaxine mepesuccinateb	homoharringtonine	Synribo®	chronic myeloid leukemia
2012	crofelemerc	Croton lechleri oligomeric proanthocyanidins	Fulyzaq®	HIV/AIDS anti-retroviral-associated diarrhea
2013	ado-trastuzumab emtansine (protein-bound)b	maytansine	Kadcyla®	breast cancer
2013	ospemifeneb	phytoestrogens	Osphena®	menopause-associated dyspareunia

^aInformation taken from the Drugs@FDA database (http://www.accessdata.fda.gov/scripts/cder/drugsatfda).

^bNew molecular entity.

^cApproved as a mixture of compounds as a “botanical drug”.